Emmaus Life Sciences, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
OQB
10-K: Emmaus Life Sciences Reports FY2024 Results, Cites Revenue Decline and Going Concern Uncertainty
Emmaus Life Sciences' 10-K filing reveals a significant revenue drop in 2024 and raises substantial doubt about the company's ability to continue as a going concern.
OQB
Emmaus Life Sciences secures a short-term $700,000 loan with a high interest rate, while also facing ongoing financial reporting issues and material weaknesses in internal controls.